Evidence map›Paper›PMID 35069869›Full record

ArticleExperimental and therapeutic medicine2022

CBL knockdown protects cardiomyocytes against hypoxia-reoxygenation injury by downregulating GRB2 expression.

Zhengbing Lv, Xiaojia Luo, Biying Hong, Qiran Ye, Jianxiong Liu, Yongmei Hu

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Tyrosine Kinases and Endothelial Homeostasis in Pulmonary Arterial Hypertension: Too Hot to Handle?American journal of respiratory cell and molecular biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhengbing LvDepartment of Cardiology, The Second People's Hospital of Chengdu, Chengdu, Sichuan 610017, P.R. China.
Xiaojia LuoDepartment of Cardiology, The Second People's Hospital of Chengdu, Chengdu, Sichuan 610017, P.R. China.
Biying HongDepartment of Cardiology, The Second People's Hospital of Chengdu, Chengdu, Sichuan 610017, P.R. China.
Qiran YeDepartment of Biotechnology, College of Life Science Sichuan University, Chengdu, Sichuan 610000, P.R. China.
Jianxiong LiuDepartment of Cardiology, The Second People's Hospital of Chengdu, Chengdu, Sichuan 610017, P.R. China.
Yongmei HuDepartment of Cardiology, The Second People's Hospital of Chengdu, Chengdu, Sichuan 610017, P.R. China.
Chengdu Second People's Hospital · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial ischemia-reperfusion injury (MIRI) is an event that follows a myocardial infarction. As such, close observation and appropriate patient management is paramount in the treatment process of interventional surgery. The pathogenesis of MIRI has not been fully elucidated. Therefore, the aim of the present study was to explore of novel targets for MIRI treatment whilst also determining their possible underlying mechanism of action. The plasma samples used in the present study were collected from 30 patients with ischemic cardiomyopathy and 30 healthy volunteers. H9c2 rat cardiomyoblasts were subjected to hypoxia and reoxygenation (H/R) modeling to establish an

Indexed as

Cbl proto-oncogenegrowth factor receptor-bound protein 2H9c2 cellshypoxia-reoxygenation injurymyocardial ischemia-reperfusion injury

Identifiers

PMID35069869
PMCPMC8764905
OpenAlexW4206776540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.